Molecular analysis of the digestive microbiota in a gnotobiotic mouse model during antibiotic treatment: Influence of Saccharomyces boulardii

Anaerobe

Volumn 14, Issue 4, 2008, Pages 229-233

  Barc, Marie Claude ^a   Charrin Sarnel, Céline ^a   Rochet, Violaine ^b   Bourlioux, François ^a   Sandré, Catherine ^a   Boureau, Hélène ^a   Doré, Joël ^b   Collignon, Anne ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b CEMAGREF   (France)

Author keywords

Antibiotics; Fecal microbiota; Molecular methods; Saccharomyces boulardii

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; BACTEROIDES; BIFIDOBACTERIUM; CLOSTRIDIUM; CLOSTRIDIUM HISTOLYTICUM; CONTROLLED STUDY; ENTEROBACTERIACEAE; ENTEROCOCCUS; EXPERIMENTAL MODEL; FECES MICROFLORA; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GNOTOBIOTICS; INTESTINE FLORA; LACTOBACILLUS; MOUSE; NONHUMAN; NUCLEIC ACID PROBE; PORPHYROMONAS; PREVOTELLA; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; COLONY COUNT, MICROBIAL; FECES; FLOW CYTOMETRY; GASTROINTESTINAL TRACT; GERM-FREE LIFE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; RNA, BACTERIAL; RNA, RIBOSOMAL, 16S; SACCHAROMYCES;

BACTERIA (MICROORGANISMS); BACTEROIDES; BIFIDOBACTERIUM; CLOSTRIDIUM COCCOIDES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM HISTOLYTICUM; ENTEROBACTERIACEAE; ENTEROBACTERIALES; ENTEROCOCCUS; EUBACTERIUM RECTALE; FAECALIBACTERIUM PRAUSNITZII; LACTOBACILLUS; MUS; PORPHYROMONAS; PREVOTELLA; SACCHAROMYCES BOULARDII;

EID: 51049116216     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2008.04.003     Document Type: Article

References (47)

1. McFarland L.V. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis Sci 16 (1998) 292-307
2. Sullivan C., Edlund C., and Nord C.E. Effects of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 1 (2001) 101-114
3. Fuller R. Probiotics in human medicine. Gut 32 (1991) 439-442
4. Marteau P., de Vrese M., Cellier C.J., and Schrezenmeir J. Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 73 (2001) 430S-436S
5. Mc Farland L.V., Surawicz C.M., Greenberg R.N., Elmer G.W., Moyer K., Melcher S.A., et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 90 (1995) 439-448
6. Surawicz C.M., Elmer G.W., Speelman P., Mc Farland L.V., Chinn J., and Van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii. A prospective study. Gastroenterology 96 (1989) 981-988
7. Czerucka D., and Rampal P. Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4 (2002) 733-739
8. Corthier G., Dubos, and Ducluzeau R. Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii. Can J Microbiol 32 (1986) 894-896
9. Elmer G.W., and Mc Farland L.V. Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters. Antimicrob Agents Chemother 31 (1987) 129-131
10. Mc Farland L.V., Surawicz C.M., Danko L., and Greenberg R.N. Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. Aliment Pharmacol Ther 13 (1999) 1663-1668
11. Mc Farland L.V., Surawicz C.M., Greenberg R.N., Fekety R., Elmer G.W., Moyer K., et al. Randomized placebo controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271 (1994) 1913-1918
12. Surawicz C.M., Mc Farland L.V., Elmer G., and Chinn J. Treatment of recurrent Clostridium difficile colitis with vancomycin and Saccharomyces boulardii. Am J Gastroenterol 84 (1989) 1285-1287
13. Surawicz C.M., Mc Farland L.V., Greenberg R.N., Rubin M., Fekety R., Mulligan M.E., et al. The search for a better treatment for recurrent Clostridium difficile disease: Use a high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31 (2000) 1012-1017
14. Suau A., Bonnet R., Sutren M., Godon J.J., Gibson G.R., Collins M.D., et al. Direct analysis of genes encoding 16S rRNA from complex communities reveal many novel molecular species within the human gut. Appl Environ Microbiol 65 (1999) 4799-4807
15. Amann R.I., Krumlolz L., and Stalh D.A. Fluorescent oligonucleotide probing of whole cells for determinative, phylogenic and environmental studies in microbiology. J Bacteriol 2 (1990) 762-770
16. Franks A.H., Harmsen H.J.M., Raangs G.C., Jansen G.J., Schut F., and Welling G.W. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16s rRNA-tergeted oligonucleotide probes. Appl Environ Microbiol 64 (1998) 3336-3345
17. Amann R.I., Binder B.J., Olson R.J., Chrisholm S.W., Devereux R., and Stalh D.A. Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analysing mixed microbial populations. Appl Environ Microbiol 56 (1990) 1919-1925
18. Vaughan E.E., Schut F., Heilig H.G.H.J., Zoetendal E.G., de Vos W.M., and Akkermans A.D.L. A molecular view of the intestinal ecosystem. Curr Issues Intest Microbiol 11 (2000) 1-12
19. Waltner G., Amann R., and Beisker W. Optimizing fluorescent in situ hybridization with RNA-targeted oligonucleotides probes for flow cytometric identification of microorganisms. Cytometry 14 (1993) 136-143
20. Rigottier-Gois L., Le Bourhis A.G., Gramet G., Rochet V., and Doré J. Fluorescent hybridization combined with flow cytometry and hybridization of total RNA to analyse the composition of microbial communities in human feces using 16S rRNA probes. FEMS Microbiol Ecol 1456 (2003) 1-9
21. Barc M.C., Bourlioux F., Rigottier-Gois L., Charrin-Sarnel C., Janoir C., Boureau H., et al. Effect of amoxicillin clavulanic acid on human fecal flora in a gnotobiotic mouse model assessed with fluorescence hybridization using group specific 16S rRNA probes in combination with flow cytometry. Antimicrob Agents Chemother 48 (2004) 1365-1368
22. Wong W.C., Hentges D.J., and Dougherty S.H. Adequacy of the human fecal microbiota associated mouse as a model for studying the ecology of the human intestinal tract. Microbial Ecol Health Dis 9 (1996) 187-198
23. Imaoka A., Setoyama H., Takagi A., Matsumoto S., and Umesaki Y. Improvement of human faecal flora-associated mouse model for evaluation of the functional foods. J Appl Microbiol 96 (2004) 656-663
24. Raibaud P., Ducluzeau R., Dubos F., Hudault S., Bewa H., and Muller M.C. Implantation of bacteria from the digestive tract of man and various animals into gnotobiotic mice. Am J Clin Nutr 33 (1980) 2440-2447
25. Hazenberg M.P., Bakker M., and Verschoor-Burggraaf A. Effects of the human intestinal microflora on germ-free mice. J Appl Bacteriol 50 (1981) 95-106
26. Hirayama K., Kawamura S., and Mitsuoka T. Development and stability of human fecal flora in the intestine of ex-germ-free mice. Microb Ecol Health Dis 4 (1991) 95-99
27. Saquet E., Raibaud P., and Garnier J. Etude comparée de la microflore de l'estomac, de l'intestin grêle et du caecum du rat holoxénique. Ann Inst Pasteur (Paris) 120 (1971) 501-524
28. Adlerberth I., Cerquetti M., Poilane I., Wold A., and Collignon A. Mechanisms of colonisation and colonisation resistance of the digestive tract. Microb Ecol Health Dis 11 (2000) 223-229
29. Sghir A., Gramet G., Suau A., Rochet V., Pochart P., and Doré J. Quantification of bacterial groups within human fecal flora by oligonucleotide probe hybridization. Appl Environ Microbiol 66 (2000) 2263-2266
30. Bléhaut H., Massot J., Elmer G.W., and Levy R.H. Disposition kinetics of Saccharomyces boulardii in man and rat. Biopharm Drug Disp 10 (1989) 353-364
31. Philippe-Taine G., Coroler L., Levy R.H., and Gillardin J.M. Dose-Dependent preventive effect of Saccharomyces boulardii on clindamycin-induced alterations in intestinal aerobic flora of the hamster. Microbial Ecol Health Dis 15 (2003) 126-130
32. Tannock G.W., Munro K., Harmsen H.J.M., Welling G.W., Smart J., and Gopal P.K. Analysis of the fecal microflora of human subjects consuming a probiotic containing Lactobacillus rhamnosus DR20. Appl Environ Microbiol 6 (2000) 2578-2588
33. Beaugerie L., Flahaut A., Barbut F., Atlan P., Lalande V., Cousin P., et al. Antibiotic-associated diarrhea and Clostridium difficile in the community. Aliment Pharmacol Ther 17 (2001) 905-912
34. Turck D., Bernet J.P., Marx J., Kempf H., Giard P., Walbaum O., et al. Incidence and risk factors for oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 37 (2003) 22-26
35. Beaugerie L., Flahaut A., Barbut F., Atlan P., Lalande V., Cousin P., et al. Antibiotic-associated diarrhea and Clostridium difficile in the community. Aliment Pharmacol Ther 17 (2003) 905-912
36. Wistrom J., Norrby S.R., Myhre E.B., Eriksson S., Granstrom G., Lagergren L., et al. Frequency of antibiotic-associated diarrhea in 2462 antibiotic-treated hospitalized patients: A prospective study. J Antimicrob Chemother 47 (2001) 43-50
37. Hoffmann A.F. Bile acids, diarrhea, and antibiotics: data, speculation, and unifying hypothesis. J Infect Dis 135 (1977) S126-S132
38. Hogenauer C., Hammer H.F., Krejs G.J., and Reisinger E.C. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis 27 (1998) 702-710
39. Rao S.S., Edwards C.A., Austeen C.J., Bruce C., and Read N.W. Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 94 (1988) 928-932
40. Young V.B., and Schmidt T.M. Antibiotic-associated diarrhea accompanied by large-scale alterations on the composition of the fecal microbiota. J Clin Microbiol 42 (2004) 1203-1206
41. Castagliuolo I., Riegler M.F., Valenick L., LaMont J.T., and Pothoulakis C. Saccharomyces boulardii protease mediates Clostridium difficile toxins A and B effects in human colonic mucosa. Infect Immun 67 (1999) 302-307
42. Pothoulakis C., Kelly C.P., Joshi M.A., Gao N., O'Keane C.J., Castagliuolo I., et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology 104 (1993) 1108-1115
43. Tasteyre A., Barc M.C., Karjalainen T., Bourlioux P., and Collignon A. Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. Microb Pathogen 32 (2002) 219-225
44. Gedek B.R. Adherence of Escherichia coli serogroup 0157 and Salmonella typhimunium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses 42 (1999) 261-264
45. Qamar A., Aboudola S., Warny M., Michetti P., Pothoulakis C., Lamont J.T., et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun 69 (2001) 2762-2765
46. Buts J.P., Bernasconi P., Vaerman J.P., and Dive C. Stimulation of secretory IgA and secretory component of immunoglobulin in small intestine of rats treated with Saccharomyces boulardii. Digest Dis Sci 35 (1990) 251-256
47. Sougioultzis S., Simeonidis S., Bhaskar K.R., Chen X., Anton P.M., Keates S., et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 341 (2006) 69-76